Basics Kura Oncology, Inc. Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. IPO Date: September 16, 2015 Sector: Healthcare Industry: Biotech Market Cap: $530.7M Activated in VL: True Average Daily Range Avg Daily Range: $0.39 | 2.81% Avg Daily Range (30 D): $0.14 | 2.31% Avg Daily Range (90 D): $0.17 | 2.65% Institutional Daily Volume Avg Daily Volume: .48M Avg Daily Volume (30 D): 1.09M Avg Daily Volume (90 D): 1.06M Trade Size Avg Trade Size (Sh.): 91 Avg Trade Size (Sh.) (30 D): 96 Avg Trade Size (Sh.) (90 D): 92 Institutional Trades Total Inst.Trades: 2,832 Avg Inst. Trade: $1.85M Avg Inst. Trade (30 D): $1.22M Avg Inst. Trade (90 D): $1.27M Avg Inst. Trade Volume: .12M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.01M Avg Closing Trade (30 D): $1.21M Avg Closing Trade (90 D): $1.21M Avg Closing Volume: 129.69K     News Jun 2, 2025 @ 10:00 PM Kura Oncology and Kyowa Kirin Report Positive Pivo... Source: N/A Jun 1, 2025 @ 11:00 PM Kura Oncology and Kyowa Kirin Announce FDA Accepta... Source: N/A May 22, 2025 @ 9:30 PM Kura Oncology and Kyowa Kirin Announce Pivotal Mon... Source: N/A Sep 30, 2024 @ 10:30 PM Kura Oncology Announces Publication of Ziftomenib ... Source: Kura Oncology, Inc. Jun 24, 2024 @ 11:30 AM Kura Oncology Reports Preclinical Data Supporting ... Source: Kura Oncology, Inc. Financials   TTM Q3 2024 Q2 2024 Basic EPS $-.66 $-.63 $-.59 Diluted EPS $-.66 $-.63 $-.59 Revenue $ 14.11M $ $ Gross Profit $ $ $ Net Income / Loss $ -57.43M $ -54.4M $ -50.84M Operating Income / Loss $ -64.7M $ $ Cost of Revenue $ $ $ Net Cash Flow $ -173.19M $ 4.3M $ 3.68M PE Ratio